Latest Headlines
-
North County Biotech Laboratories Has Immediate Availability Of Single-Tenant, Fully Equipped Laboratory Spaces For Life Science Companies In The San Diego Region
9/17/2020
North County Biotech Laboratories (NCBL), provider of fully equipped, private, and secure laboratories with offices in North County San Diego for development and growth of innovative, novel therapies and medicines, announces immediate availability
-
Prevencio Develops Highly Accurate, Artificial Intelligence-Driven Blood Test For Kawasaki Disease
9/17/2020
Prevencio, Inc. today announces the development of a highly accurate blood test, HART KD, for diagnosis of Kawasaki disease.
-
VirIntel Launches VirIntel COVID-19 Antibody Test, Delivering Superior Accuracy
9/17/2020
VirIntel, LLC has developed and commercialized a COVID-19 antibody test with demonstrated 100% specificity and 94% sensitivity in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection
-
Accelerate Diagnostics Announces New FDA Clearance For Accelerate PhenoTest® Improvements
9/16/2020
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the Company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and expand the system's antimicrobial susceptibility testing (AST) menu for bloodstream infections
-
Roche Receives FDA Approval For Expanded Use Of The CINtec PLUS Cytology Test To Aid Clinicians In Preventing Cervical Cancer
9/16/2020
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec® PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV)
-
ImmunoGenomics And Vero Diagnostics Providing COVID-19 Testing With Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay On Biomark HD Platform
9/16/2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that ImmunoGenomics, based in metropolitan Houston, and Vero Diagnostics of Research Triangle Park, North Carolina, are among the Clinical Laboratory Improvement Amendments (CLIA) certified labs now offering testing services using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD system
-
Todos Medical Expands Partnership With Care G.B. Plus For Proprietary TBIA Cancer Tests To Include Europe, Israel And Africa
9/16/2020
Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has expanded its partnership with Care G.B. Plus (Care GB) for the development and commercialization of its proprietary TBIA cancer diagnostic platform (Todos Cancer Tests) to include Europe, Israel and Africa
-
Innatoss Laboratories Launches Neutralizing Antibody Public Testing Service For SARS-CoV-2 In Europe Using GenScript's cPass™ Kit
9/15/2020
Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit
-
Bionano Genomics Expands Its Diagnostic Testing Menu With Launch Of Lineagen’s EpiPanelDx PLUS Gene Panel Test That Identifies Genetic Conditions Related To Epilepsy
9/14/2020
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the release of EpiPanelDx PLUS™ by its diagnostics services business, Lineagen. The new laboratory developed test (LDT) and associated clinical support bolsters Lineagen’s diagnostic services for physicians providing care for pediatric patients with neurodevelopmental disorders (NDDs)
-
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Achieves CE Mark
9/14/2020
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has achieved CE Mark under the European In‐Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex® Respiratory Pathogen Panel 2 (RP2)